Basal serum pancreatic polypeptide is dependent on age and gender in an adult population.

This study is the first epidemiologically based study of basal levels of serum pancreatic polypeptide (s-PP). The basal level of serum PP has become a field of interest mainly due to the role of PP as an endocrine tumour marker, and as a marker of pancreatic neuroendocrine function after pancreas transplantation and in the case of diabetic autonomic neuropathy. The study population consisted of primarily Caucasian adults representative of a general population living around Copenhagen. Serum pancreatic polypeptide was measured in random serum samples from fasting persons (n = 623), aged 25-64 y, using a monospecific radioimmunoassay. Fasting serum pancreatic polypeptide depended on age and gender. The results demonstrated that fasting pancreatic polypeptide levels increase exponentially with age. Fitted separately for each sex, basal serum pancreatic polypeptide was found to increase by approximately 3% per year of age. Males had higher concentrations of pancreatic polypeptide in serum compared to age-matched females. Normal range and 95% reference intervals are given. The lower limit for the reference interval of the normal range was close to detection limit. We conclude that discrepancies among earlier reports on the fasting levels of serum pancreatic polypeptide are most likely due to lack of adjustment for age and gender. Thus, variation due to age and gender should be considered in evaluating fasting levels of serum pancreatic polypeptide. Whether similar considerations are important when evaluating stimulated serum pancreatic polypeptide levels remains to be elucidated.

[1]  D. Kendall,et al.  The Defective Glucagon Response From Transplanted Intrahepatic Pancreatic Islets During Hypoglycemia Is Transplantation Site–Determined , 1997, Diabetes.

[2]  O. Cummings,et al.  Pancreatic Polypeptide Immunoreactivity in Sporadic Gastrinoma: Relationship to Intraabdominal Location , 1995, Pancreas.

[3]  P. Cryer,et al.  Hypoglycemia-Induced Autonomic Failure in IDDM is Specific for Stimulus of Hypoglycemia and Is Not Attributable to Prior Autonomic Activation , 1994, Diabetes.

[4]  A. Masclee,et al.  Plasma cholecystokinin and pancreatic polypeptide secretion in response to bombesin, meal ingestion and modified sham feeding in lean and obese persons. , 1994, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[5]  P. Cryer,et al.  Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. , 1993, The Journal of clinical investigation.

[6]  T. Schwartz,et al.  Impaired pancreatic polypeptide response to a meal in type 1 diabetic patients: vagal neuropathy or islet cell dysfunction? , 1993, Acta endocrinologica.

[7]  J. Halter,et al.  Preserved insulin secretion and insulin independence in recipients of islet autografts. , 1992, The New England journal of medicine.

[8]  H. Langstein,et al.  The utility of circulating levels of human pancreatic polypeptide as a marker for islet cell tumors. , 1990, Surgery.

[9]  J. Halter,et al.  Glucagon, catecholamine and pancreatic polypeptide secretion in type I diabetic recipients of pancreas allografts. , 1990, The Journal of clinical investigation.

[10]  T. M. Hayes,et al.  Unawareness of hypoglycaemia and inadequate hypoglycaemic counterregulation: no causal relation with diabetic autonomic neuropathy. , 1990, BMJ.

[11]  A. Hanukoglu,et al.  Human Pancreatic Polypeptide in Children and Young Adults , 1990, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[12]  J. Bülow,et al.  Endogenous pancreatic polypeptide in different vascular beds: relationship to release and degradation in subjects with normal and decreased kidney function. , 1986, Metabolism: clinical and experimental.

[13]  A. Shulkes,et al.  Metabolism of neurotensin and pancreatic polypeptide in man: role of the kidney and plasma factors. , 1984, The Journal of clinical endocrinology and metabolism.

[14]  H. Imura,et al.  Hyperfunction of the Entero-PP Axis in Non-Insulin Dependent Diabetes Mellitus , 1983, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[15]  J. G. Daly,et al.  Radioimmunoassay for pancreatic polypeptide, and its age-related changes in concentration. , 1983, Clinical chemistry.

[16]  M. Entman,et al.  Absence of hepatic extraction of pancreatic polypeptide in conscious dogs. , 1983, The American journal of physiology.

[17]  W. Hagopian,et al.  Predominance of renal and absence of hepatic metabolism of pancreatic polypeptide in the dog. , 1983, The American journal of physiology.

[18]  W. Zipf,et al.  Blunted pancreatic polypeptide responses in children with obesity of Prader-Willi syndrome. , 1981, The Journal of clinical endocrinology and metabolism.

[19]  R. McLeod,et al.  Human pancreatic polypeptide: studies of fasting and postprandial plasma concentrations. , 1980, Canadian journal of physiology and pharmacology.

[20]  M. Rudnick,et al.  Human pancreatic polypeptide in chronic renal failure and cirrhosis of the liver: role of kidneys and liver in pancreatic polypeptide metabolism. , 1980, The Journal of clinical endocrinology and metabolism.

[21]  B. Vialettes,et al.  Low Plasma Levels of Pancreatic Polypeptide in Obesity , 1980, Diabetes.

[22]  I. Correas,et al.  Reduced pancreatic polypeptide secretion in obese subjects. , 1980, The Journal of clinical endocrinology and metabolism.

[23]  J. Gauldie,et al.  Motilin, human pancreatic polypeptide (HPP) and gastrin plasma concentrations in fasting subjects. , 1979, Clinical biochemistry.

[24]  S. Fajans,et al.  Effect of age on fasting plasma levels of pancreatic hormones in man. , 1978, The Journal of clinical endocrinology and metabolism.

[25]  J. A. Hedo,et al.  Fluctuations of Human Pancreatic Polypeptide in Plasma: Effect of Normal Food Ingestion and Fasting 1 , 1978, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[26]  E. Passaro,et al.  IS PANCREATIC POLYPEPTIDE A MARKER FOR ZOLLINGER-ELLISON SYNDROME? , 1978, The Lancet.

[27]  J. Holst,et al.  Vagal, cholinergic regulation of pancreatic polypeptide secretion. , 1978, The Journal of clinical investigation.

[28]  H. Bruckner,et al.  Circulating pancreatic polypeptide in patients with adenocarcinoma of the bile duct. , 1993, Acta oncologica.

[29]  J. Olesen,et al.  Epidemiology of headache in a general population--a prevalence study. , 1991, Journal of clinical epidemiology.

[30]  P. Cryer,et al.  Subnormal pancreatic polypeptide and epinephrine responses to insulin-induced hypoglycemia identify patients with insulin-dependent diabetes mellitus predisposed to develop overt autonomic neuropathy. , 1988, Annals of internal medicine.

[31]  W. Bauman,et al.  Pancreatic polypeptide in Pima Indians: the influence of obesity and diabetes. , 1985, Metabolism: clinical and experimental.

[32]  J. Holst,et al.  Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human morbid obesity. , 1983, International journal of obesity.

[33]  T. Schwartz,et al.  Synchronous oscillations in the basal secretion of pancreatic-polypeptide and gastric acid. Depression by cholinergic blockade of pancreatic-polypeptide concentrations in plasma. , 1979, Gastroenterology.

[34]  P. Bouman,et al.  IS PHENYLALANINE SUPERIOR TO LEUCINE AS LABELED SUBSTRATE FOR INSULIN-BIOSYNTHESIS IN RAT PANCREATIC-ISLETS , 1978 .

[35]  R. Chance,et al.  A newly recognized pancreatic polypeptide; plasma levels in health and disease. , 1976, Recent progress in hormone research.